Full Text
PCV21 A BENEFIT-RISK ASSESSMENT OF USING CYP2C19 GENOTYPE INFORMATION TO GUIDE ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME

Abstract

Authors

GF Guzauskas D Veenstra D Hughes

Back to Volume 13, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×